STAT

Opinion: Overdiagnosis and disease labels: the case of polycystic ovary syndrome

Labeling people with a disease that has mild symptoms, if any, and only a low risk of getting worse may do more harm than good, physically and emotionally.

Advances in medical technology make it easier to detect disease earlier than ever. That’s a good thing when it means a deadly cancer can be caught promptly and stopped with treatment. But it isn’t so good for people who are labeled with a disease that has mild symptoms, if any, and only a low risk of getting worse. Such a diagnosis may do more harm than good, especially if the diagnosis adds an emotional burden and doesn’t change an individual’s treatment.

Take polycystic ovary syndrome, also known as PCOS, one of several overdiagnosed conditions we study. Symptoms of this hormonal and metabolic disorder include menstrual irregularities, not ovulating during a menstrual cycle, the development of type 2 diabetes and potentially to cardiovascular disease.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks